Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Detalles Bibliográficos
Autores principales: Westerman, Mary E., Wood, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475466/
https://www.ncbi.nlm.nih.gov/pubmed/32953837
http://dx.doi.org/10.21037/atm.2020.03.217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475466/
https://www.ncbi.nlm.nih.gov/pubmed/32953837
http://dx.doi.org/10.21037/atm.2020.03.217

Ejemplares similares